I might work to have (new, outside) consultants find, define or exclude potential noncancer causes of the CEA rise. Also a skillful doctor could use multiple markers and panels to better define cancer correlated measurements. We have shadow boxed less visibly defined mets for some years. In several situations, multiple blood tests can be more sensitive, predictive or reassuring than scans; obviously best used together.
In our blood data set, advances in different markers correlate with adjuvant ingredients too low or missing, sometimes it's very pronounced. If a cancer marker advances, we make extra effort to stop it with off label adjuvants, like celebrex and high potency supplements added to daily oral chemo, like an extended immunochemo version of ADAPT. Some materials are targetable. By some indices, the cumulative effect of these off label adjuvants is more than is achievable with regular chemo.
We bolstered platelets and WBC with PSK. Improved immune function with WGP type beta glucans also improved immunochemo performance.
watchful, active caregiver for stage IVb CC since early 2010. immuno"Chemo forever," for mCRC